A Study of GV20-0251 in Patients With Solid Tumor Malignancies
Status:
Not yet recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study of GV20-0251 being developed for the treatment of patients with
advanced solid tumors, who are refractory to approved therapies or other standard of care.